All In Biotech

Drug Trial Radar · NCT04888715

To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers

An Open Label, 2-part, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between "DWN12088" and "Pirfenidone" or "Nintedanib" in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jul 23, 2021

Primary completion

Aug 2, 2021

Study completion Aug 18, 2021

Sponsor

Sponsor type
Industry
First posted
May 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between DWN12088 and Pirfenidone or Nintedanib in healthy volunteers

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • DWN12088Drug

    Prolyl-tRNA synthetase (PRS) inhibitor

  • PirfenidoneDrug

    Pirfenidone

  • NintedanibDrug

    Nintedanib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of Pirfenidone and DWN12088Time frame: 0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour
  2. AUC of Pirfenidone and DWN12088Time frame: 0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour
  3. Cmax of Nintedanib and DWN12088Time frame: 0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour
  4. AUC of Nintedanib and DWN12088Time frame: 0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cha Unitersity Bundang Medical Center

    Seongnam-si, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.